IP Library Granted Patent US 7,807,442
Granted Patent B2
US 7,807,442 · App. 11/777,275 · Granted Oct 5, 2010

PUFA polyketide synthase systems and uses thereof

Assignee: Martek Biosciences Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,442
App. No.
11/777,275
Granted
Oct 5, 2010
Kind
B2
Abstract

The invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems isolated from or derived from non-bacterial organisms, to homologues thereof, to isolated nucleic acid molecules and recombinant nucleic acid molecules encoding biologically active domains of such a PUFA PKS system, to genetically modified organisms comprising PUFA PKS systems, to methods of making and using such systems for the production of bioactive molecules of interest, and to novel methods for identifying new bacterial and non-bacterial microorganisms having such a PUFA PKS system.

Claims (22)

1. A genetically modified microorganism, wherein the microorganism has been transfected with at least one recombinant nucleic acid molecule encoding a polyketide synthase (PKS) system for the production of polyunsaturated fatty acids (PUFAs), wherein the PKS system comprises the following proteins:

a) a protein comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:2 and has β-keto acyl-ACP synthase (KS) activity, malonyl-CoA:ACP acyltransferase (MAT) activity, acyl carrier protein (ACP) activity and ketoreductase (KR) activity;

b) a protein comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:4 and has β-keto acyl-ACP synthase (KS) activity, chain length factor (CLF) activity, acyl transferase (AT) activity, and enoyl ACP-reductase (ER) activity; and

c) a protein comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:6 and has FabA-like β-hydroxy acyl-ACP dehydrase (DH) activity and enoyl ACP-reductase (ER) activity.

2. The genetically modified microorganism of claim 1 , wherein the protein of (a) comprises the amino acid sequence of SEQ ID NO:2.

3. The genetically modified microorganism of claim 1 , wherein the protein of (b) comprises the amino acid sequence of SEQ ID NO:4.

4. The genetically modified microorganism of claim 1 , wherein the protein of (c) comprises the amino acid sequence of SEQ ID NO:6.

5. The genetically modified microorganism of claim 1 , wherein the PKS system comprises:

a) a protein comprising the amino acid sequence of SEQ ID NO:2;

b) a protein comprising the amino acid sequence of SEQ ID NO:4; and

c) a protein comprising the amino acid sequence of SEQ ID NO:6.

6. The genetically modified microorganism of claim 1 , wherein the protein of (a) is encoded by SEQ ID NO:1.

7. The genetically modified microorganism of claim 1 , wherein the protein of (b) is encoded by SEQ ID NO:3.

8. The genetically modified microorganism of claim 1 , wherein the protein of (c) is encoded by SEQ ID NO:5.

9. The genetically modified microorganism of claim 1 , wherein the microorganism is further transfected with a phosphopantetheinyl transferase (PPTase).

10. The genetically modified microorganism of claim 1 , wherein the microorganism has been further genetically modified to recombinantly express at least one nucleic acid molecule encoding at least one biologically active domain from a PKS system selected from the group consisting of: a bacterial PUFA PKS system, a Type I PKS system, a Type II PKS system, a modular PKS system, and a non-bacterial PUFA PKS system.

11. The genetically modified microorganism of claim 1 , wherein the microorganism produces docosahexaenoic acid (DHA).

12. The genetically modified microorganism of claim 1 , wherein the microorganism produces docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA).

13. The genetically modified microorganism of claim 1 , wherein the microorganism produces a polyunsaturated fatty acid (PUFA) profile that differs from the naturally occurring microorganism without a genetic modification.

14. The genetically modified microorganism of claim 1 , wherein the microorganism is a Thraustochytrid.

15. The genetically modified microorganism of claim 1 , wherein the microorganism is a bacterium.

16. A method to produce at least one polyunsaturated fatty acid (PUFA), comprising growing the genetically modified microorganism of claim 1 , to produce at least one PUFA.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2012
From: MARTEK BIOSCIENCES CORPORATION
To: DSM IP ASSETS B.V.
Reel/Frame 028938/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2012
From: MARTEK BIOSCIENCES BOULDER CORPORATION
To: MARTEK BIOSCIENCES CORPORATION
Reel/Frame 028921/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2012
From: METZ, JAMES G.; FLATT, JAMES H.; KUNER, JERRY M.; BARCLAY, WILLIAM R.
To: MARTEK BIOSCIENCES BOULDER CORPORATION
Reel/Frame 028920/0651 →
Continuity (6)
Division 1012480000 · Apr 16, 2002
Continuation In Part 0923189900 · Jan 14, 1999
Provisional Application 6032326900 · Sep 18, 2001
Provisional Application 6029879600 · Jun 15, 2001
Provisional Application 6028406600 · Apr 16, 2001
Related Publication 20080038791A1 · Feb 14, 2008